TEL AVIV, ISRAEL, October 31, 2022 /24-7PressRelease/ —
• Squalus Scientific renames itself as BT BeaMedical Technologies (BeaMed)
• BeaMed strikes to fresh locations of work in Caesarea Israel and receives ISO13485 certification for its fresh facility as fragment of its FDA 510(okay) regulatory pathway for obtaining advertising clearance in the U.S.
Squalus Scientific, a inside of most firm growing a fresh laser basically based mostly platform for epilepsy and most cancers surgical operation, has decided to rebrand itself as BT BeaMedical Technologies (BeaMed) as fragment of its market entry technique into the U.S. market.
BeaMed is the inventor and developer of the StingRay Laser Machine (the “StingRay Machine”), a fresh laser-basically based mostly thermal ablation abilities designed for therapy of previously inoperable circumstances of epilepsy and for improvement of outcomes and enablement of fresh therapy suggestions for oncology procedures, alongside side those treating brain, prostate, liver, breast and lung cancers.
The StingRay Machine combines fresh fiber optic abilities with an developed laser console and computerized luminous defend a watch on, that allows a supreme match between the bid structure of tumors and epileptic focal aspects and the energy offer, while holding foremost life like areas in opposition to thermal destroy. The console integrates developed imaging modalities, and guides the doctor, making sure the therapy is adjusted to the bid patient wants with precise time energy defend a watch on.
“We’re overjoyed with the event BeaMed is making against growing a product that could doubtlessly aid millions of sufferers globally tormented by epilepsy and most cancers. The rebranding of the firm fits our product vision and is a first step in growing a particular and strong tag in the surgical neighborhood,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals, BeaMed’s lead investor.
“As we switch forward with vogue and product introduction, we desired to plan a tag which captures the essence of our abilities and our distinctive aspects, alongside side the progressive exhaust of laser beam emission to fit the bid wants of each and each patient. In addition, we’re pleased to voice the completion of certification of the fresh firm under ISO13485 in our fresh station of industrial house, step one in our 510(okay) regulatory approval technique,” said Gil Shapira, co-founding father of BeaMed.
BeaMed was once basically based by Moshe Eshkol and Gil Shapira, each and each extremely skilled specialists in surgical lasers and scientific devices. BeaMed and the reach of the StingRay procedure are also supported by a particular prestigious grant from the BIRD Foundation (https://www.birdf.com/), a bi-nationwide group supporting Israel-US collaboration. Gil Shapira brings forward 26+ years of engineering and product vogue and administration trip, with over 17 years in the surgical laser industry. Gil owns and manages neoLaser, a firm he basically based in 2012, and led to earnings enhance and profitability, with a 43% CAGR on its formulation to bigger than 1200 international installations and performing 50,000+ surgical procedures each and each year in over 30 countries. Previously, Gil led product vogue and advertising at OmniGuide, a a success high-enhance laser basically based mostly scientific tool lope-off out of the Massachusetts Institute of Technology (MIT).
Contact Information:
www.beam-med.com
[email protected]
BeaMed is the inventor and developer of the StingRay Laser Machine (the “StingRay Machine”), a fresh laser-basically based mostly thermal ablation abilities designed for therapy of previously inoperable circumstances of epilepsy and for improvement of outcomes and enablement of fresh therapy suggestions for oncology procedures, alongside side those treating brain, prostate, liver, breast and lung cancers.
# # #
